Research development of povidone-iodine in clinical applications of ophthalmology_West China Medical Journal

Authors：

YIN Wen ¹ , WANG Song ¹ , LU Xiangheng ¹ , XIAO Xiao ² , ZHANG Wenqiu ¹ ,  LIU Chunling ¹

1. Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
2. Frontiers Science Center for Disease-related Molecular Network, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

LIU Chunling, Email: liuchunling@wchscu.cn

Keywords：

Povidone-iodine; disinfection; conjunctivitis; endophthalmitis; cataract surgery

DOI：

10.7507/1002-0179.202507016

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Povidone-iodine, an indispensable broad-spectrum and low-resistance antimicrobial agent in ophthalmology, holds dual therapeutic value: it serves as a preoperative conjunctival sac disinfectant to effectively prevent postoperative endophthalmitis, and as adjuvant therapy for refractory infectious eye diseases that respond poorly to conventional treatments. This article systematically summarizes the progress of clinical research on povidone-iodine, focusing on in-depth discussions of core issues such as the mechanism by which it achieves sterilization through free iodine, the controversy over concentration and exposure time in practical applications, and ocular surface safety. The aim is to provide a solid scientific basis for the standardized clinical application and future research of povidone-iodine.

1.	Zamora JL. Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions. Am J Surg, 1986, 151(3): 400-406.
2.	Lepelletier D, Maillard JY, Pozzetto B, et al. Povidone iodine: properties, mechanisms of action, and role in infection control and Staphylococcus aureus decolonization. Antimicrob Agents Chemother, 2020, 64(9): 00682-20.
3.	Singh S, Sawant OB, Mian SI, et al. Povidone-iodine attenuates viral replication in ocular cells: implications for ocular transmission of RNA viruses. Biomolecules, 2021, 11(5): 753.
4.	Lachapelle JM, Castel O, Casado AF, et al. Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Clin Pract, 2013, 10(5): 579.
5.	Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, et al. Povidone iodine in wound healing: a review of current concepts and practices. Int J Surg, 2017, 44: 260-268.
6.	Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology, 2002, 109(1): 13-24.
7.	Jaissle GB, Szurman P, Bartz-Schmidt KU, et al. Recommendation for the implementation of intravitreal injections--statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monbl Augenheilkd, 2005, 222(5), 390-395.
8.	Grzybowski A, Kanclerz P, Myers WG. The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol, 2018, 29(1): 19-32.
9.	Speaker MG, Milch FA, Shah MK, et al. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology, 1991, 98(5): 639-649.
10.	Friedman DA, Mason JO 3rd, Emond T, et al. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina, 2013, 33(5): 975-981.
11.	Merani R, Hunyor AP. Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. Int J Retina Vitreous, 2015, 1(1): 9.
12.	Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina, 2012, 32(3): 473-476.
13.	中華醫學會眼科學分會眼底病學組, 中華醫學會眼科學分會白內障及屈光手術學組中華醫學會眼科學分會眼外傷學組, 中華醫學會眼科學分會青光眼學組. 中國眼科手術后感染性眼內炎診療專家共識 (2022 年). 中華眼科雜志, 2022, 58(7): 487-499.
14.	Borgia A, Mazzuca D, Della Corte M, et al. Prophylaxis of ocular infection in the setting of intraocular surgery: implications for clinical practice and risk management. Ophthalmol Ther, 2023, 12(2): 735.
15.	Ratnumnoi R, Keorochana N, Sontisombat C. Normal flora of conjunctiva and lid margin, as well as its antibiotic sensitivity, in patients undergoing cataract surgery at Phramongkutklao Hospital. Clin Ophthalmol, 2017, 11: 237-241.
16.	Gnanasekaran S, Rogers S, Wickremasinghe S, et al. The effect of diluting povidone-iodine on bacterial growth associated with speech. BMC Ophthalmol, 2019, 19(1): 62.
17.	Miller KM, Oetting TA, Tweeten JP, et al. Cataract in the adult eye preferred practice pattern. Ophthalmology, 2022, 129(1): P1-P126.
18.	中華醫學會眼科學分會白內障及屈光手術學組. 中國成人白內障摘除手術指南 (2023 年). 中華眼科雜志, 2023, 59(12): 977-987.
19.	Koerner JC, George MJ, Meyer DR, et al. Povidone-iodine concentration and dosing in cataract surgery. Surv Ophthalmol, 2018, 63(6): 862-868.
20.	Li B, Nentwich MM, Hoffmann LE, et al. Comparison of the efficacy of povidone-iodine 1.0%, 5.0%, and 10.0% irrigation combined with topical levofloxacin 0.3% as preoperative prophylaxis in cataract surgery. J Cataract Refract Surg, 2013, 39(7): 994-1001.
21.	Teren D, Neuman G, Abulafia A, et al. In vivo assessment of antimicrobial activity and toxicity of repeated 1% povidone-iodine applications vs a single 5% povidone-iodine application. J Cataract Refract Surg, 2024, 50(7): 682-687.
22.	Shimada H, Arai S, Nakashizuka H, et al. Reduction of anterior chamber contamination rate after cataract surgery by intraoperative surface irrigation with 0. 25% povidone-iodine. Am J Ophthalmol, 2011, 151(1): 11-17.
23.	Ta CN, Singh K, Egbert PR, et al. Prospective comparative evaluation of povidone-iodine (10% for 5 minutes versus 5% for 1 minute) as prophylaxis for ophthalmic surgery. J Cataract Refract Surg, 2008, 34(1): 171-172.
24.	張碩基. 白內障術前 5%聚維酮碘對結膜囊抑菌作用和角膜上皮影響的研究. 重慶: 中國人民解放軍陸軍軍醫大學, 2019.
25.	Ferguson AW, Scott JA, McGavigan J, et al. Comparison of 5% povidone-iodine solution against 1% povidone-iodine solution in preoperative cataract surgery antisepsis: a prospective randomised double blind study. Br J Ophthalmol, 2003, 87(2): 163-167.
26.	Tofighi N, Gohari M, Sadeh M, et al. Effects of chloramphenicol, povidone-iodine 1% and 5% eye drops on the colonisation of conjunctival flora in patients undergoing cataract surgery. Ghana Med J, 2023, 57(2): 79-86.
27.	Peden MC, Hammer ME, Su?er IJ. Dilute povidone-iodine prophylaxis maintains safety while improving patient comfort after intravitreal injections. Retina, 2019, 39(11): 2219-2224.
28.	Patel SN, Gangaputra S, Sternberg P Jr, et al. Prophylaxis measures for postinjection endophthalmitis. Surv Ophthalmol, 2020, 65(4): 408-420.
29.	Panahibazaz M, Moosavian M, Khataminia G, et al. Sub-conjunctival injection of antibiotics vs. povidone-iodine drop on bacterial colonies in phacoemulsification cataract surgery. Jundishapur J Microbiol, 2014, 7(9): e13108.
30.	Shimada H, Nakashizuka H, Hattori T, et al. Prophylaxis for acute scleral buckle infection using 0. 25% povidone-iodine ocular surface irrigation during surgery. Int Ophthalmol, 2014, 34(2): 211-216.
31.	Sawant OB, How S, Hurlbert S, et al. Effect of increasing povidone-iodine exposure on corneal epithelium and impact on donor rim cultures. Cornea, 2022, 41(12): 1553-1558.
32.	Lindquist TD, Maxwell AJ, Miller TD, et al. Preparation of corneal donor eyes comparing 1% versus 5% povidone-iodine. Cornea, 2011, 30(3): 333-337.
33.	Azzaro C, Meduri A, Oliverio G W, et al. The use of venous catheter and irrigation with povidone-iodine 0. 6% in patients with punctal and proximal canalicular stenosis: preliminary report. J Clin Med, 2024, 13(5): 1330.
34.	中華醫學會眼科學分會白內障及人工晶狀體學組. 我國白內障摘除手術后感染性眼內炎防治專家共識 (2017 年). 中華眼科雜志, 2017, 53(11): 810-813.
35.	Barry P, Cordovés L, Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. European Society of Cataract and Refractive Surgeons, 2013: 1-44.
36.	Grzybowski A, Shimada H, Nakashizuka H, et al. Low-concentration povidone-iodine for the prevention of intraocular infections in ophthalmic surgery. Curr Opin Ophthalmol, 2022, 33(1): 28-34.
37.	Edington M, Ramaesh K, Lockington D. Virucidal benefits of povidone-iodine use on the ocular surface: a review. BMJ Open Ophthalmology, 2020, 5(1): e000509.
38.	Hadad R, Hedengran A, Barnils A, et al. Effect of chlorhexidine, povidone‐iodine and betadine antiseptic eye drops on cultured human conjunctival goblet cell survival. Acta Ophthalmol, 2024, 102(7): 773-778.
39.	Swift W, Bair JA, Chen W, et al. Povidone iodine treatment is deleterious to human ocular surface conjunctival cells in culture. BMJ Open Ophthalmol, 2020, 5(1): e000545.
40.	ElKitkat RS, Ebeid WM, Habib EK, et al. Safety of intracameral injection of minimal bactericidal concentration of povidone iodine on the corneal endothelium in a rabbit model. Cornea, 2016, 35(1): 72-76.
41.	蔣勁, 姚克, 章征. 不同濃度國產聚維酮碘對兔角膜毒性損傷的評價. 中華眼科雜志, 2006, 42(4): 338-340.
42.	Kim S, Ahn Y, Lee Y, et al. Toxicity of povidone-iodine to the ocular surface of rabbits. BMC Ophthalmol, 2020, 20(1): 359.
43.	Shimada H, Nakashizuka H. Cataract surgery by intraoperative surface irrigation with 0. 25% povidone-iodine. J Clin Med, 2021, 10(16): 3611.
44.	Silas MR, Schroeder RM, Thomson RB, et al. Optimizing the antisepsis protocol: effectiveness of 3 povidone-iodine 1.0% applications versus a single application of povidone-iodine 5.0%. J Cataract Refract Surg, 2017, 43(3): 400-404.
45.	Koerner J, Grzybowski A. Povidone-iodine pharmacokinetics and study design. BMC Ophthalmology, 2020, 20(1): 29.
46.	Ambrosino CM, Shen LL, Mahjoub H, et al. Povidone-iodine in vitro antiseptic efficacy as a function of exposure duration, concentration, preparation, and length of storage. Graefes Arch Clin Exp Ophthalmol, 2024, 262(12): 4005-4012.
47.	Grzybowski A, Told R, Sacu S, et al. 2018 update on intravitreal injections: Euretina expert consensus recommendations. Ophthalmologica, 2018, 239(4): 181-193.
48.	中華醫學會眼科學分會眼底病學組. 我國視網膜病玻璃體腔注藥術質量控制標準. 中華眼科雜志, 2015, 51(12): 892-895.
49.	Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina, 2014, 34(Suppl 12): S1-S18.
50.	任新軍, 柯屹峰, 譚亮章, 等. 玻璃體腔注射藥物前結膜囊培養結果分析. 中華眼底病雜志, 2024, 40(9): 687-692.
51.	Saedon H, Nosek J, Phillips J, et al. Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutan Ocul Toxicol, 2017, 36(4): 343-346.
52.	Pepose JS, Ahuja A, Liu W, et al. Randomized, controlled, phase 2 trial of povidone-iodine/dexamethasone ophthalmic suspension for treatment of adenoviral conjunctivitis. Am J Ophthalmol, 2018, 194: 7-15.
53.	Chintakuntlawar AV, Chodosh J. Cellular and tissue architecture of conjunctival membranes in epidemic keratoconjunctivitis. Ocul Immunol Inflamm, 2010, 18(5): 341-345.
54.	Dang RM, Watt K, Hui A. Povidone iodine for the treatment of adenoviral conjunctivitis. Clin Exp Optom, 2021, 104(3): 308-314.
55.	Yates KA, Shanks RMQ, Kowalski RP, et al. The in vitro evaluation of povidone-iodine against multiple ocular adenoviral types. J Ocul Pharmacol Ther, 2019, 35(2): 132-136.
56.	Than T, Morettin CE, Harthan JS, et al. Efficacy of a single administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis. Am J Ophthalmol, 2021, 231: 28-38.
57.	Soleimani M, Tabatabaei SA, Mirzaei A, et al. The effect of povidone-iodine 2% eye drops in the treatment of adenoviral keratoconjunctivitis. Oman J Ophthalmol, 2023, 16(1): 69-74.
58.	Yazar H, Yarbag A, Balci M, et al. The effects of povidone iodine (pH 4. 2) on patients with adenoviral conjunctivitis. J Pak Med Assoc, 2016, 66(8): 968-970.
59.	Chen YS, Hsu CH, Chang HC. Efficacy of povidone-iodine-containing therapies for treatment of adenoviral conjunctivitis: a systematic review and network meta-analysis. Acta Ophthalmol, 2023, 101(7): 826-827.
60.	Isenberg SJ, Apt L, Valenton M, et al. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol, 2002, 134(5): 681-688.
61.	Kapoor VS, Evans JR, Vedula SS. Interventions for preventing ophthalmia neonatorum. Cochrane Database Syst Rev, 2020, 9(9): CD001862.
62.	Isenberg SJ, Apt L, Yoshimori R, et al. Povidone-iodine for ophthalmia neonatorum prophylaxis. Am J Ophthalmol, 1994, 118(6): 701-706.
63.	Ali Z, Khadije D, Elahe A, et al. Prophylaxis of ophthalmia neonatorum comparison of betadine, erythromycin and no prophylaxis. J Trop Pediatr, 2007, 53(6): 388-392.
64.	Khor WB, Prajna VN, Garg P, et al. The Asia cornea society infectious keratitis study: a prospective multicenter study of infectious keratitis in Asia. Am J Ophthalmol, 2018, 195: 161-170.
65.	Song X, Xie L, Tan X, et al. A multi-center, cross-sectional study on the burden of infectious keratitis in China. PloS One, 2014, 9(12): e113843.
66.	中華醫學會眼科學分會角膜病學組. 感染性角膜病臨床診療專家共識(2011 年). 中華眼科雜志, 2012, 48(1): 72-75.
67.	中華醫學會眼科學分會眼外傷學組. 中國外傷性感染性眼內炎防治專家共識 (2023 年). 中華眼科雜志, 2023, 59(2): 90-95.
68.	棘阿米巴角膜炎診斷與治療專家共識(2023)制定小組, 中國醫師協會眼科醫師分會眼感染學組. 棘阿米巴角膜炎診斷與治療專家共識(2023). 中華實驗眼科雜志, 2023, 41(10): 953-960.
69.	Ting DSJ, Ho CS, Cairns J, et al. Seasonal patterns of incidence, demographic factors and microbiological profiles of infectious keratitis: the Nottingham infectious keratitis study. Eye (Lond), 2021, 35(9): 2543-2549.
70.	Beukelman CJ, van den Berg AJJ, Hoekstra MJ, et al. Anti-inflammatory properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro. Burns, 2008, 34(6): 845-855.
71.	Eming SA, Smola-Hess S, Kurschat P, et al. A novel property of povidon-iodine: inhibition of excessive protease levels in chronic non-healing wounds. J Invest Dermatol, 2006, 126(12): 2731-2733.
72.	Bordin P. Corneal ulcer treated with 0. 66% nanoemulsion povidone-iodine: a case report. Am J Case Rep, 2020, 21: e919822.
73.	Bordin P. Low-concentration (0. 66%) povidone iodine treatment of a corneal ulcer in a rheumatoid arthritis patient. Am J Case Rep, 2021, 22: e928748.
74.	Redd TK, Talbott M, Cevallos V, et al. In vitro comparison of the Acanthamoeba cysticidal activity of povidone iodine, natamycin, and chlorhexidine. Ophthalmol Sci, 2021, 1(2): 100025.
75.	Castelnuovo S. Povidone iodine 0. 66% to fight pseudomonas aeruginosa in contact lens wearer: a case report. Case Rep Ophthalmol, 2022, 13(2): 398-407.
76.	Ramatchandirane B, Chandrika YM, Najeeb S. Successful management of fungal keratitis caused by multidrug-resistant cladosporium species using povidone-iodine. Cornea, 2024, 43(1): 125-128.
77.	Lee SM, Park JH, Suh SY, et al. Efficacy of intravitreal povidone-iodine administration for the treatment of Candida albicans endophthalmitis in rabbits. Exp Eye Res, 2021, 212: 108788.
78.	Tanaka H, Nakashizuka H, Mizuno Y, et al. Endogenous endophthalmitis successfully treated with intravitreal povidone-iodine injection: a case report. BMC Ophthalmol, 2020, 20(1): 217.
79.	Sakata K, Katsumoto T, Kumagai T, et al. Electroretinographic evaluations using skin electrode of eyes with bleb-related endophthalmitis following vitrectomy with 0.025% povidone iodine irrigation. Int Med Case Rep J, 2024: 447-454.
80.	Mi X, Malbin B, Lin X. Intraocular povidone iodine during pars Plana vitrectomy for severe and atypical endophthalmitis. Ophthalmic Surg Lasers Imaging Retina, 2021, 52(9): 485-490.
81.	Ricci GD, Garippa G, Cortese S, et al. In vitro larvicidal activity of ivermectin and povidone-iodine against Oestrus ovis. PLoS One, 2021, 16(10): e0259044.
82.	Pelletier JS, Capriotti K, Stewart KS, et al. Demodex blepharitis treated with a novel dilute povidone-iodine and DMSO system: a case report. Ophthalmol Ther, 2017, 6(2): 361-366.
83.	Yanai R, Yamada N, Ueda K, et al. Evaluation of povidone-iodine as a disinfectant solution for contact lenses: antimicrobial activity and cytotoxicity for corneal epithelial cells. Cont Lens Anterior Eye, 2006, 29(2): 85-91.

1. Zamora JL. Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions. Am J Surg, 1986, 151(3): 400-406.
2. Lepelletier D, Maillard JY, Pozzetto B, et al. Povidone iodine: properties, mechanisms of action, and role in infection control and Staphylococcus aureus decolonization. Antimicrob Agents Chemother, 2020, 64(9): 00682-20.
3. Singh S, Sawant OB, Mian SI, et al. Povidone-iodine attenuates viral replication in ocular cells: implications for ocular transmission of RNA viruses. Biomolecules, 2021, 11(5): 753.
4. Lachapelle JM, Castel O, Casado AF, et al. Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Clin Pract, 2013, 10(5): 579.
5. Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, et al. Povidone iodine in wound healing: a review of current concepts and practices. Int J Surg, 2017, 44: 260-268.
6. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology, 2002, 109(1): 13-24.
7. Jaissle GB, Szurman P, Bartz-Schmidt KU, et al. Recommendation for the implementation of intravitreal injections--statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monbl Augenheilkd, 2005, 222(5), 390-395.
8. Grzybowski A, Kanclerz P, Myers WG. The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol, 2018, 29(1): 19-32.
9. Speaker MG, Milch FA, Shah MK, et al. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology, 1991, 98(5): 639-649.
10. Friedman DA, Mason JO 3rd, Emond T, et al. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina, 2013, 33(5): 975-981.
11. Merani R, Hunyor AP. Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. Int J Retina Vitreous, 2015, 1(1): 9.
12. Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina, 2012, 32(3): 473-476.
13. 中華醫學會眼科學分會眼底病學組, 中華醫學會眼科學分會白內障及屈光手術學組中華醫學會眼科學分會眼外傷學組, 中華醫學會眼科學分會青光眼學組. 中國眼科手術后感染性眼內炎診療專家共識 (2022 年). 中華眼科雜志, 2022, 58(7): 487-499.
14. Borgia A, Mazzuca D, Della Corte M, et al. Prophylaxis of ocular infection in the setting of intraocular surgery: implications for clinical practice and risk management. Ophthalmol Ther, 2023, 12(2): 735.
15. Ratnumnoi R, Keorochana N, Sontisombat C. Normal flora of conjunctiva and lid margin, as well as its antibiotic sensitivity, in patients undergoing cataract surgery at Phramongkutklao Hospital. Clin Ophthalmol, 2017, 11: 237-241.
16. Gnanasekaran S, Rogers S, Wickremasinghe S, et al. The effect of diluting povidone-iodine on bacterial growth associated with speech. BMC Ophthalmol, 2019, 19(1): 62.
17. Miller KM, Oetting TA, Tweeten JP, et al. Cataract in the adult eye preferred practice pattern. Ophthalmology, 2022, 129(1): P1-P126.
18. 中華醫學會眼科學分會白內障及屈光手術學組. 中國成人白內障摘除手術指南 (2023 年). 中華眼科雜志, 2023, 59(12): 977-987.
19. Koerner JC, George MJ, Meyer DR, et al. Povidone-iodine concentration and dosing in cataract surgery. Surv Ophthalmol, 2018, 63(6): 862-868.
20. Li B, Nentwich MM, Hoffmann LE, et al. Comparison of the efficacy of povidone-iodine 1.0%, 5.0%, and 10.0% irrigation combined with topical levofloxacin 0.3% as preoperative prophylaxis in cataract surgery. J Cataract Refract Surg, 2013, 39(7): 994-1001.
21. Teren D, Neuman G, Abulafia A, et al. In vivo assessment of antimicrobial activity and toxicity of repeated 1% povidone-iodine applications vs a single 5% povidone-iodine application. J Cataract Refract Surg, 2024, 50(7): 682-687.
22. Shimada H, Arai S, Nakashizuka H, et al. Reduction of anterior chamber contamination rate after cataract surgery by intraoperative surface irrigation with 0. 25% povidone-iodine. Am J Ophthalmol, 2011, 151(1): 11-17.
23. Ta CN, Singh K, Egbert PR, et al. Prospective comparative evaluation of povidone-iodine (10% for 5 minutes versus 5% for 1 minute) as prophylaxis for ophthalmic surgery. J Cataract Refract Surg, 2008, 34(1): 171-172.
24. 張碩基. 白內障術前 5%聚維酮碘對結膜囊抑菌作用和角膜上皮影響的研究. 重慶: 中國人民解放軍陸軍軍醫大學, 2019.
25. Ferguson AW, Scott JA, McGavigan J, et al. Comparison of 5% povidone-iodine solution against 1% povidone-iodine solution in preoperative cataract surgery antisepsis: a prospective randomised double blind study. Br J Ophthalmol, 2003, 87(2): 163-167.
26. Tofighi N, Gohari M, Sadeh M, et al. Effects of chloramphenicol, povidone-iodine 1% and 5% eye drops on the colonisation of conjunctival flora in patients undergoing cataract surgery. Ghana Med J, 2023, 57(2): 79-86.
27. Peden MC, Hammer ME, Su?er IJ. Dilute povidone-iodine prophylaxis maintains safety while improving patient comfort after intravitreal injections. Retina, 2019, 39(11): 2219-2224.
28. Patel SN, Gangaputra S, Sternberg P Jr, et al. Prophylaxis measures for postinjection endophthalmitis. Surv Ophthalmol, 2020, 65(4): 408-420.
29. Panahibazaz M, Moosavian M, Khataminia G, et al. Sub-conjunctival injection of antibiotics vs. povidone-iodine drop on bacterial colonies in phacoemulsification cataract surgery. Jundishapur J Microbiol, 2014, 7(9): e13108.
30. Shimada H, Nakashizuka H, Hattori T, et al. Prophylaxis for acute scleral buckle infection using 0. 25% povidone-iodine ocular surface irrigation during surgery. Int Ophthalmol, 2014, 34(2): 211-216.
31. Sawant OB, How S, Hurlbert S, et al. Effect of increasing povidone-iodine exposure on corneal epithelium and impact on donor rim cultures. Cornea, 2022, 41(12): 1553-1558.
32. Lindquist TD, Maxwell AJ, Miller TD, et al. Preparation of corneal donor eyes comparing 1% versus 5% povidone-iodine. Cornea, 2011, 30(3): 333-337.
33. Azzaro C, Meduri A, Oliverio G W, et al. The use of venous catheter and irrigation with povidone-iodine 0. 6% in patients with punctal and proximal canalicular stenosis: preliminary report. J Clin Med, 2024, 13(5): 1330.
34. 中華醫學會眼科學分會白內障及人工晶狀體學組. 我國白內障摘除手術后感染性眼內炎防治專家共識 (2017 年). 中華眼科雜志, 2017, 53(11): 810-813.
35. Barry P, Cordovés L, Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. European Society of Cataract and Refractive Surgeons, 2013: 1-44.
36. Grzybowski A, Shimada H, Nakashizuka H, et al. Low-concentration povidone-iodine for the prevention of intraocular infections in ophthalmic surgery. Curr Opin Ophthalmol, 2022, 33(1): 28-34.
37. Edington M, Ramaesh K, Lockington D. Virucidal benefits of povidone-iodine use on the ocular surface: a review. BMJ Open Ophthalmology, 2020, 5(1): e000509.
38. Hadad R, Hedengran A, Barnils A, et al. Effect of chlorhexidine, povidone‐iodine and betadine antiseptic eye drops on cultured human conjunctival goblet cell survival. Acta Ophthalmol, 2024, 102(7): 773-778.
39. Swift W, Bair JA, Chen W, et al. Povidone iodine treatment is deleterious to human ocular surface conjunctival cells in culture. BMJ Open Ophthalmol, 2020, 5(1): e000545.
40. ElKitkat RS, Ebeid WM, Habib EK, et al. Safety of intracameral injection of minimal bactericidal concentration of povidone iodine on the corneal endothelium in a rabbit model. Cornea, 2016, 35(1): 72-76.
41. 蔣勁, 姚克, 章征. 不同濃度國產聚維酮碘對兔角膜毒性損傷的評價. 中華眼科雜志, 2006, 42(4): 338-340.
42. Kim S, Ahn Y, Lee Y, et al. Toxicity of povidone-iodine to the ocular surface of rabbits. BMC Ophthalmol, 2020, 20(1): 359.
43. Shimada H, Nakashizuka H. Cataract surgery by intraoperative surface irrigation with 0. 25% povidone-iodine. J Clin Med, 2021, 10(16): 3611.
44. Silas MR, Schroeder RM, Thomson RB, et al. Optimizing the antisepsis protocol: effectiveness of 3 povidone-iodine 1.0% applications versus a single application of povidone-iodine 5.0%. J Cataract Refract Surg, 2017, 43(3): 400-404.
45. Koerner J, Grzybowski A. Povidone-iodine pharmacokinetics and study design. BMC Ophthalmology, 2020, 20(1): 29.
46. Ambrosino CM, Shen LL, Mahjoub H, et al. Povidone-iodine in vitro antiseptic efficacy as a function of exposure duration, concentration, preparation, and length of storage. Graefes Arch Clin Exp Ophthalmol, 2024, 262(12): 4005-4012.
47. Grzybowski A, Told R, Sacu S, et al. 2018 update on intravitreal injections: Euretina expert consensus recommendations. Ophthalmologica, 2018, 239(4): 181-193.
48. 中華醫學會眼科學分會眼底病學組. 我國視網膜病玻璃體腔注藥術質量控制標準. 中華眼科雜志, 2015, 51(12): 892-895.
49. Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina, 2014, 34(Suppl 12): S1-S18.
50. 任新軍, 柯屹峰, 譚亮章, 等. 玻璃體腔注射藥物前結膜囊培養結果分析. 中華眼底病雜志, 2024, 40(9): 687-692.
51. Saedon H, Nosek J, Phillips J, et al. Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutan Ocul Toxicol, 2017, 36(4): 343-346.
52. Pepose JS, Ahuja A, Liu W, et al. Randomized, controlled, phase 2 trial of povidone-iodine/dexamethasone ophthalmic suspension for treatment of adenoviral conjunctivitis. Am J Ophthalmol, 2018, 194: 7-15.
53. Chintakuntlawar AV, Chodosh J. Cellular and tissue architecture of conjunctival membranes in epidemic keratoconjunctivitis. Ocul Immunol Inflamm, 2010, 18(5): 341-345.
54. Dang RM, Watt K, Hui A. Povidone iodine for the treatment of adenoviral conjunctivitis. Clin Exp Optom, 2021, 104(3): 308-314.
55. Yates KA, Shanks RMQ, Kowalski RP, et al. The in vitro evaluation of povidone-iodine against multiple ocular adenoviral types. J Ocul Pharmacol Ther, 2019, 35(2): 132-136.
56. Than T, Morettin CE, Harthan JS, et al. Efficacy of a single administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis. Am J Ophthalmol, 2021, 231: 28-38.
57. Soleimani M, Tabatabaei SA, Mirzaei A, et al. The effect of povidone-iodine 2% eye drops in the treatment of adenoviral keratoconjunctivitis. Oman J Ophthalmol, 2023, 16(1): 69-74.
58. Yazar H, Yarbag A, Balci M, et al. The effects of povidone iodine (pH 4. 2) on patients with adenoviral conjunctivitis. J Pak Med Assoc, 2016, 66(8): 968-970.
59. Chen YS, Hsu CH, Chang HC. Efficacy of povidone-iodine-containing therapies for treatment of adenoviral conjunctivitis: a systematic review and network meta-analysis. Acta Ophthalmol, 2023, 101(7): 826-827.
60. Isenberg SJ, Apt L, Valenton M, et al. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol, 2002, 134(5): 681-688.
61. Kapoor VS, Evans JR, Vedula SS. Interventions for preventing ophthalmia neonatorum. Cochrane Database Syst Rev, 2020, 9(9): CD001862.
62. Isenberg SJ, Apt L, Yoshimori R, et al. Povidone-iodine for ophthalmia neonatorum prophylaxis. Am J Ophthalmol, 1994, 118(6): 701-706.
63. Ali Z, Khadije D, Elahe A, et al. Prophylaxis of ophthalmia neonatorum comparison of betadine, erythromycin and no prophylaxis. J Trop Pediatr, 2007, 53(6): 388-392.
64. Khor WB, Prajna VN, Garg P, et al. The Asia cornea society infectious keratitis study: a prospective multicenter study of infectious keratitis in Asia. Am J Ophthalmol, 2018, 195: 161-170.
65. Song X, Xie L, Tan X, et al. A multi-center, cross-sectional study on the burden of infectious keratitis in China. PloS One, 2014, 9(12): e113843.
66. 中華醫學會眼科學分會角膜病學組. 感染性角膜病臨床診療專家共識(2011 年). 中華眼科雜志, 2012, 48(1): 72-75.
67. 中華醫學會眼科學分會眼外傷學組. 中國外傷性感染性眼內炎防治專家共識 (2023 年). 中華眼科雜志, 2023, 59(2): 90-95.
68. 棘阿米巴角膜炎診斷與治療專家共識(2023)制定小組, 中國醫師協會眼科醫師分會眼感染學組. 棘阿米巴角膜炎診斷與治療專家共識(2023). 中華實驗眼科雜志, 2023, 41(10): 953-960.
69. Ting DSJ, Ho CS, Cairns J, et al. Seasonal patterns of incidence, demographic factors and microbiological profiles of infectious keratitis: the Nottingham infectious keratitis study. Eye (Lond), 2021, 35(9): 2543-2549.
70. Beukelman CJ, van den Berg AJJ, Hoekstra MJ, et al. Anti-inflammatory properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro. Burns, 2008, 34(6): 845-855.
71. Eming SA, Smola-Hess S, Kurschat P, et al. A novel property of povidon-iodine: inhibition of excessive protease levels in chronic non-healing wounds. J Invest Dermatol, 2006, 126(12): 2731-2733.
72. Bordin P. Corneal ulcer treated with 0. 66% nanoemulsion povidone-iodine: a case report. Am J Case Rep, 2020, 21: e919822.
73. Bordin P. Low-concentration (0. 66%) povidone iodine treatment of a corneal ulcer in a rheumatoid arthritis patient. Am J Case Rep, 2021, 22: e928748.
74. Redd TK, Talbott M, Cevallos V, et al. In vitro comparison of the Acanthamoeba cysticidal activity of povidone iodine, natamycin, and chlorhexidine. Ophthalmol Sci, 2021, 1(2): 100025.
75. Castelnuovo S. Povidone iodine 0. 66% to fight pseudomonas aeruginosa in contact lens wearer: a case report. Case Rep Ophthalmol, 2022, 13(2): 398-407.
76. Ramatchandirane B, Chandrika YM, Najeeb S. Successful management of fungal keratitis caused by multidrug-resistant cladosporium species using povidone-iodine. Cornea, 2024, 43(1): 125-128.
77. Lee SM, Park JH, Suh SY, et al. Efficacy of intravitreal povidone-iodine administration for the treatment of Candida albicans endophthalmitis in rabbits. Exp Eye Res, 2021, 212: 108788.
78. Tanaka H, Nakashizuka H, Mizuno Y, et al. Endogenous endophthalmitis successfully treated with intravitreal povidone-iodine injection: a case report. BMC Ophthalmol, 2020, 20(1): 217.
79. Sakata K, Katsumoto T, Kumagai T, et al. Electroretinographic evaluations using skin electrode of eyes with bleb-related endophthalmitis following vitrectomy with 0.025% povidone iodine irrigation. Int Med Case Rep J, 2024: 447-454.
80. Mi X, Malbin B, Lin X. Intraocular povidone iodine during pars Plana vitrectomy for severe and atypical endophthalmitis. Ophthalmic Surg Lasers Imaging Retina, 2021, 52(9): 485-490.
81. Ricci GD, Garippa G, Cortese S, et al. In vitro larvicidal activity of ivermectin and povidone-iodine against Oestrus ovis. PLoS One, 2021, 16(10): e0259044.
82. Pelletier JS, Capriotti K, Stewart KS, et al. Demodex blepharitis treated with a novel dilute povidone-iodine and DMSO system: a case report. Ophthalmol Ther, 2017, 6(2): 361-366.
83. Yanai R, Yamada N, Ueda K, et al. Evaluation of povidone-iodine as a disinfectant solution for contact lenses: antimicrobial activity and cytotoxicity for corneal epithelial cells. Cont Lens Anterior Eye, 2006, 29(2): 85-91.

West China Medical Journal

Latest ArticlesResearch development of povidone-iodine in clinical applications of ophthalmology

Abstract Full text Figures/Tables Video References Cited by

Format

Content